MedTech Resources

Company

Dexcom

Funding, FDA decisions, device trials, adverse event reports and recalls filed under this company's name in public data. Records are matched by name, so a subsidiary or an unusual spelling can be missed.

Last checked: Nov 19, 2026Source: SEC EDGAR, openFDA and ClinicalTrials.govMethods & limitations

Dexcom is on our public-company list (ticker DXCM). Naming a company here is not a recommendation of it or of any security.

Financing

Public company. Figures from its SEC financial statements, plus private placements it reported on Form D.

Public

Listed

DXCM

Nasdaq · DEXCOM INC

Public float

$34.2B

Value of shares held by non-insiders on Jun 30, 2025

Revenue

$4.66B

Fiscal year ending Dec 31, 2025

Net income

$836M

Fiscal year ending Dec 31, 2025

R&D spending

$599M

Fiscal year ending Dec 31, 2025

Cash

$961M

As of Sep 30, 2026

Long-term debt

$1.24B

As of Sep 30, 2026

Shares outstanding

373.0M

As of Oct 22, 2026

Capital raised as a public company

Cash received from selling stock and borrowing, from each year's cash-flow statement in the annual report. Fiscal years, by the year each one ended.

YearIPOStock soldLong-term debtConvertible debt
2025–$28.1M––
2024–$28.2M––
2023–$26.6M–$1.23B
2022–$22.5M––
2021–$20.3M––

Private placements (Form D)

One row per Form D offering, newest first. The amount raised is the latest amended figure. An offering can run for months and close in several tranches. Matched by company name, so check the filing.

First saleTypeRaisedRound sizeInvestorsExemption and agentFiling
May 2, 2016Equity

Issued in a merger or acquisition; not counted as money raised

$7.2M$7.2M2Rule 506(b)Form D ↗May 18, 2016

Company details

From the company's latest Form D.

Legal name
DEXCOM INC
Headquarters
San Diego, California
Incorporated
Delaware over five years before filing
Entity type
Corporation
Revenue range
Decline to Disclose
Industry filed under
Biotechnology

Executives, directors and promoters

As listed on the latest Form D.

  • Richard DoubledayExecutive Officer
  • Eric TopolDirector
  • Barbara KahnDirector
  • Steven PacelliExecutive Officer
  • Jonathan LordDirector
  • Jeffrey MoyExecutive Officer
  • Nicholas AugustinosDirector
  • Terrance GreggExecutive Officer, Director
  • Jorge ValdesExecutive Officer
  • John ListerExecutive Officer
  • Jess RoperExecutive Officer
  • Andrew BaloExecutive Officer
  • Jay SkylerDirector
  • Kevin SayerExecutive Officer, Director

Not in public filings: valuations, share prices and investors' names. Private databases such as PitchBook and Crunchbase estimate these from press releases and surveys. Not every round is filed: companies raising under other exemptions, or from foreign investors only, may not file Form D. Nothing here is investment advice.

Investors

5%+ shareholders from SEC Schedule 13D/13G filings since Dec 1, 2024, and SBIR/STTR grants (NIH through Nov 10, 2026, other agencies through 2023). Venture investors in private rounds are not in public filings.

The investor database is part of the paid tier

For Dexcom we have 4 shareholders with 5% or more.

It is included for signed-in readers who have credit, along with the daily news digest. Credit is also what pays for AI device summaries.

Latest FDA decisions

The 8 newest of 29 since 2015.

Search the Clearance Tracker

Device trials

Trials on ClinicalTrials.gov that list this company as lead sponsor, most recently updated first.

Open in the Trial Radar

Reports received

331,569

Received Nov 1, 2025 to Nov 19, 2026. Includes 211 of another or unstated type.

Malfunction reports

323,697

98% of reports

Injury reports

7,607

2.3% of reports

Death reports

54

0.0% of reports

Adverse event reports received per month

Reports that name this company as manufacturer, by the date FDA received them. The newest month is incomplete.

Search the MAUDE Monitor
  • Malfunction
  • Injury
  • Death
  • Other
View as table
MonthMalfunctionInjuryDeathOther
Dec 2323,25629701
Jan 2427,36043310
Feb 2423,20134810
Mar 2422,54334120
Apr 2426,32435810
May 2428,04440220
Jun 2424,70655650
Jul 2433,52346611
Aug 2432,05839812
Sep 2430,03746241
Oct 2431,83040921
Nov 2429,17035611
Dec 2426,91042333
Jan 2527,71748930
Feb 2520,96451130
Mar 2525,72346700
Apr 2527,45047110
May 2531,37258803
Jun 2531,97061111
Jul 2537,74773634
Aug 2535,16375452
Sep 2532,82669936
Oct 2532,12868341
Nov 2521,50056060
Dec 2522,10864830
Jan 2677,74258241
Feb 2619,55948360
Mar 2621,98161850
Apr 2618,65559730
May 2618,01263040
Jun 2623,13162680
Jul 2626,725715640
Aug 2626,740677579
Sep 2623,475824052
Oct 2624,069647439
Nov 260000

Recent recalls

From FDA's recall database. FDA lists each recalled product separately, so one recall can appear several times. A recall is often a correction or a labeling change, not a removal from the market.

Showing the 8 newest of 29 recall records in FDA's data.

Back to all tools

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.